Answers are grounded in this paper and cite their sources.
Dosimetric analysis demonstrates improved treatment outcomes in advanced cervical cancer patients, suggesting clinical application may enhance survival and reduce toxicity.
The dual-modality system has the potential to enhance treatment outcomes in CC by optimizing tumor coverage while reducing toxicity. Future clinical trials should assess its impact on patient survival and treatment-related side effects to bridge the gap between dosimetric improvements and clinical application.
No takes yet. Share an insight, caveat, or question.
Fengwen Tang (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: